Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015
Walters, M.Spalding.; Grass, J.E.; Bulens, S.N.; Hancock, E.B.; Phipps, E.C.; Muleta, D.; Mounsey, J.; Kainer, M.A.; Concannon, C.; Dumyati, G.; Bower, C.; Jacob, J.; Cassidy, P.Maureen.; Beldavs, Z.; Culbreath, K.; Phillips, W.E.; Hardy, D.J.; Vargas, R.L.; Oethinger, M.; Ansari, U.; Stanton, R.; Albrecht, V.; Halpin, A.Laufer.; Karlsson, M.; Rasheed, J.Kamile.; Kallen, A.
Emerging Infectious Diseases 25(7): 1281-1288
Pseudomonas aeruginosa is intrinsically resistant to many antimicrobial drugs, making carbapenems crucial in clinical management. During July-October 2015 in the United States, we piloted laboratory-based surveillance for carbapenem-resistant P. aeruginosa (CRPA) at sentinel facilities in Georgia, New Mexico, Oregon, and Tennessee, and population-based surveillance in Monroe County, NY. An incident case was the first P. aeruginosa isolate resistant to antipseudomonal carbapenems from a patient in a 30-day period from any source except the nares, rectum or perirectal area, or feces. We found 294 incident cases among 274 patients. Cases were most commonly identified from respiratory sites (120/294; 40.8%) and urine (111/294; 37.8%); most (223/280; 79.6%) occurred in patients with healthcare facility inpatient stays in the prior year. Genes encoding carbapenemases were identified in 3 (2.3%) of 129 isolates tested. The burden of CRPA was high at facilities under surveillance, but carbapenemase-producing CRPA were rare.